Allysta Pharmaceuticals
Latest round
- Series A
Last raised
- Apr 2019
Total raised
- $15M
Investors
- 1
About Allysta Pharmaceuticals
Allysta Pharmaceuticals, Inc.Founded in 2013, Allysta Pharmaceuticals, Inc. is based in Belmont, US. The company specializes in biopharmaceutical products aimed at rare diseases.Allysta Pharmaceuticals specializes in developing innovative biopharmaceutical products targeting rare diseases with significant unmet medical needs. The company's core product offering is ALY688ER, an extended-release formulation designed to deliver the active compound ALY688 throughout the body efficiently. ALY688 functions as a potent and selective activator of adiponectin signaling pathways, which are critical for regulating metabolic processes and combating conditions associated with obesity. The primary end use case for ALY688ER is in the treatment of Duchenne muscular dystrophy (DMD), a severe genetic disorder affecting boys, characterized by progressive muscle degeneration. The product has shown promising results in preclinical models, including reduced muscle cell death and enhanced muscle regeneration.S.Allysta Pharmaceuticals operates within a transactional framework primarily based on partnerships and direct sales to healthcare providers. The company's revenue model is expected to involve agreements with healthcare institutions and possibly collaborations with larger pharmaceutical companies for broader distribution. Transactions involve the sale of ALY688ER as part of a therapeutic regimen for patients diagnosed with DMD and potentially other inflammatory and fibrotic conditions. The pricing structure for its products is designed to reflect the advanced therapeutic benefits provided by ALY688ER, which addresses critical health challenges faced by patients. The company is targeting expansion into international markets known for high incidences of rare diseases, with specific plans to enter these regions by 2024. Furthermore, the company intends to increase its partnerships with healthcare institutions to facilitate broader distribution and enhance accessibility of its therapies.
Who invested in Allysta Pharmaceuticals
1 investor across 1 round
See all investors in Allysta Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Apr 16, 2019
Amount
$15M
Investors
Questions about Allysta Pharmaceuticals
Who invested in Allysta Pharmaceuticals?
Allysta Pharmaceuticals has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Allysta Pharmaceuticals raised?
Allysta Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Allysta Pharmaceuticals last raise money?
Allysta Pharmaceuticals's most recent round on record is a Series A, in Apr 2019.
What does Allysta Pharmaceuticals do?
Allysta Pharmaceuticals is a pharmaceuticals company.
Where is Allysta Pharmaceuticals headquartered?
Allysta Pharmaceuticals is headquartered in Belmont, US.
Which VCs invest in companies like Allysta Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Allysta Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Allysta Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.